PPT-Mind the gap: avoiding paravalvular leak using computer simulation in bicuspid transcatheter

EHJCRD2200342 July 2022 Introduction EHJCRD2200342 2 Transcatheter aortic valve replacement TAVR is becoming increasingly prevalent worldwide In 2019 the number of TAVR performed in the USA exceeded surgical aortic valve replacements SAVR 72991 vs 57626. RQLQNOLMNH573473KLOLSV57347OHFWURQLFV573471573619 3KLOLSV57347HDOWKFDUH57347UHVHUYHV57347WKH57347ULJKW57347WR57347PDNH57347FKDQJHV57347LQ57347VSHFL57536FDWLRQV57347DQG57362RU57347WR57347GLVFRQWLQXH57347DQ57347SURGXFW57347DW57347DQ57347WLPH57347ZLWKRX Dear. . Colleague,. Welcome. . to. . the. . first. . letter. . of. . the. . New. . Year. . from . the. Heart . and. . Car. d. iovasc. u. lar. . Service. . Line.. The. . Medic. a. l. College. Allan Stewart, MD., Jonathan A. Yang, MD; Mark J. Russo, MD/MPH; Alexander . Iribarne. , MD; Brendan F. Scully; Rachel . Easterwood. ; Craig R. Smith, MD; Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY. Dominik Fleischmann. Department of Radiology. Stanford University. 20. th. Annual Summer Practicum, Masters in Body Imaging. Jackson Lake Lodge, Moran, Wyoming. August 8-11, 2010. . Research support: General Electric. Operators:. Samin. K Sharma, MD, FACC, . MSCAI. Annapoorna. . Kini. , MD, MRCP, FACC. Gilbert Tang, MD, MSc, MBA, FACC. Sahil. . Khera. , MD, MPH, FACC. Parasuram. . Krishnamoorthy. , MD. Echocardiographer. Therapy and Maximising TAVI Programme Leveraging unique advantages of a TAVI portfolio for optimised outcomes and early discharge cardiovascularnews.com This educational supplement has been spo The Aortic Valve. Harry H. Holdorf PhD, MPA, RDMS, RVT, LRT, N.P.. Aortic Stenosis. Etiology. Calcific/degenerative (50% start as bicuspid). Rheumatic (Assoc. w/mitral stenosis). Congenital (bicuspid (1-2% of the population), membrane. Aortic Valve Replacement Resource Manual. Molina Allen. Overview. Identified need for resource manual:. Transcatheter. Aortic Valve Replacement (TAVR). Transition of Care. A2 .  A3. TAVR is approved for “. . . Severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement, and in who existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis” (Edwards Life Sciences, 2015).. TAVR in Low-Risk Bicuspid in Patients. John Forrest, MD. Associate Professor of Medicine. Director of Interventional Cardiology and Structural Heart Program. Yale University School of Medicine. Yale Health System. IntroductionThe bicuspid aortic valve is a common congenital car-diac anomaly, having an incidence in the general popula-tion of 0.9 to 2.0% and a frequency of 54% of all patientsag�ed 15 years 1 Disclosure Statement of Financial InterestsWithin the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) listed below.Financial RelationshipCompanyRe Bicuspid Aortic Valve Infective Endocarditis:Is There a Need to Widen the Indications for Antibiotic Prophylaxis Ramtin Anousheh, MD, MPH and Ramona MehrinfarZadeh, MD IntroductionBicuspid aortic valv Gregory Condos, MD, LCDR, MC, USN; Katherine Rees; Rasleen Grewal; Hirsch Mehta, MD; Raghava Gollapudi, MD; Karl Limmer, MD; Arvin Narula, MD. Disclosures. The authors have no relevant financial disclosures.. Evolut. Low Risk Bicuspid Study. Basel Ramlawi, MD, FACC. Valley Health System, Winchester, Virginia. For the . Evolut. Low Risk Bicuspid Investigators. Disclosure Statement of Financial Interests.